Kura Oncology, Inc.

As of October 3, 2025, Kura Oncology, Inc. shows a mildly bullish trend, supported by weekly indicators, despite bearish monthly signals and a significant 1-year underperformance of -45.68% compared to the S&P 500's 17.82%.

As of October 3, 2025, Kura Oncology, Inc. shows a mildly bullish trend with mixed technical indicators, having outperformed the S&P 500 recently but significantly lagging in long-term performance.

As of October 3, 2025, Kura Oncology, Inc. shows a mildly bullish trend with mixed signals from MACD and Bollinger Bands, having outperformed the S&P 500 recently but significantly underperformed over the past year and three years.

As of September 26, 2025, Kura Oncology, Inc. has shifted to a bullish trend supported by positive daily moving averages and weekly MACD, despite some bearish monthly indicators, while outperforming the S&P 500 in the short term but underperforming over the longer term.

As of September 26, 2025, Kura Oncology, Inc. shows a bullish trend supported by positive indicators, though caution is advised due to bearish signals in the monthly MACD and KST, with recent performance outperforming the S&P 500 in the short term but underperforming over the past year.

As of September 9, 2025, Kura Oncology, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 significantly over the past year and five years.

As of February 26, 2025, Kura Oncology, Inc. is considered overvalued with a "risky" valuation grade due to concerning financial metrics, including a Price to Book Value of 1.60, a negative ROE of -49.91%, and an EV to EBITDA ratio significantly lower than the industry average, indicating inefficiencies in generating returns and insufficient earnings relative to its enterprise value.

As of February 26, 2025, Kura Oncology, Inc. is considered overvalued and risky due to its negative P/E ratio of -2.95, a ROE of -49.91%, and poor performance with a year-to-date return of -32.61%, especially when compared to healthier peers like ADMA Biologics, Inc. and Adaptive Biotechnologies Corp.

As of May 27, 2025, Kura Oncology, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators present mixed signals.

As of March 2022, Kura Oncology's management team includes Dr. Troy Wilson as Chairman, President, and CEO, with Mr. Faheem Hasnain as Lead Independent Director and independent directors Mr. Robert Hoffman, Mr. Thomas Malley, Ms. Diane Parks, and Dr. Steven Stein.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized therapies for solid tumors and blood cancers. As of March 2025, it reported net sales of $14 million and a net loss of $57 million, with a market cap of $536.76 million.

As of Jun 18, Kura Oncology, Inc. has a market capitalization of 536.76 million and reported net sales of 67.99 million with a net profit of -181.89 million over the latest four quarters.